Oxapin (oxcarbazepine) coated tablets 300 mg. №30


Oxapin is indicated for the treatment of partial seizures with or without secondary generalized tonic-clonic seizures as monotherapy or adjunctive therapy.



Oxapin composition
Main active ingredients: 1 tablet contains 300 mg of oxcarbazepine.
Auxiliary components: microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, yellow coating Oradry 04F82783: hypromellose, polyethylene glycol, titanium dioxide, iron oxide yellow.

Release form                                                                                                                                                                        Available in tablet form, coated.

Pharmacological properties
This Oxapin belongs to the group of antiepileptic drugs.
The active ingredient manifests its activity due to its metabolite – a monohydroxy derivative. The mechanism of action is determined by blocking voltage-gated sodium channels.
This stabilizes overly excited neuronal membranes, inhibits repetitive neuronal discharges, and reduces the spread of synaptic impulses. The drug helps to protect against generalized tonic-clonic, clonic seizures and stops or reduces the frequency of seizures.
Eating food does not affect the rate and extent of drug absorption. The drug is metabolized in the liver.
Subsequently, the active component is metabolized by conjugation with glucuronic acid.

Oxapin is indicated for the treatment of partial seizures with or without secondary generalized tonic-clonic seizures as monotherapy or adjunctive therapy.

The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.

In pediatrics, the drug is used after 6 years.

Application during pregnancy and lactation
This drug is not recommended for pregnant women – only under strict indications determined by the attending physician.
If it is necessary to take the drug during breastfeeding, lactation is suspended.

Method of administration and dosage
The use of the drug should be started with a dose of 600 mg / day (8-10 mg / kg / day), divided into two applications. If clinically indicated, the dose can be increased at approximately weekly intervals by no more than 600 mg per day from the initial dose to achieve the desired clinical response. The therapeutic effect is observed in the dose range of 600-2400 mg per day.
There is evidence that in patients not currently receiving antiepileptic drugs, an effective dose of oxcarbazepine as monotherapy is 1200 mg per day.
In a controlled hospital setting, an increase in the dose to 2400 mg per day was achieved within 48 hours.

In cases of overdose, the following symptoms are possible:

  • drowsiness;
  • dizziness;
  • nausea;
  • vomiting;
  • hyperkinesis;
  • hyponatremia;
  • ataxia;
  • nystagmus.

Side effects
The drug is usually well tolerated when used in the recommended doses.
Side effects include:

  • leukopenia, thrombocytopenia, inhibition of bone marrow hematopoiesis, aplastic anemia, agranulocytosis, pancytopenia, neutropenia;
  • hyponatremia;
  • convulsions, encephalopathy, suppressed level of consciousness, confusion, visual impairment;
  • hypothyroidism, vomiting, nausea, folic acid deficiency;
  • confusion, depression, apathy, agitation, affective lability, emotional lability;
  • drowsiness, headache, dizziness, ataxia, tremor, nystagmus, impaired attention, amnesia;
  • diplopia, blurred images, blurred vision, blurred vision;
  • arrhythmia, blockade, arterial hypertension;
  • nausea, vomiting, diarrhea, constipation, abdominal pain, pancreatitis;
  • rash, baldness, acne, urticaria, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), erythema multiforme.

Storage conditions and periods
Expiration date – up to 3 years from the production date indicated on the package. Storage periods should not be exceeded.
Storage temperature should not exceed 25 ° C. Temperature deviations can change the properties of the preparation, therefore it should always be stored in its original packaging.